BioMarin - Articles and news items

NICE draft guidance recommends elosulfase alfa for MPS IVa

Industry news / 23 November 2015 / Victoria White

The positive draft guidance follows the development of a managed access scheme by BioMarin and NHS England…

Pharma companies rank high on Forbes’ most innovative list

Industry news / 19 August 2015 / Victoria White

Alexion, Regeneron,Incyte and BioMarin have all been ranked in the top ten on Forbes magazine’s 2015 list of the “World’s Most Innovative Companies”…

BioMarin provides programme update for talazoparib in metastatic breast cancer

Industry news / 21 July 2015 / Victoria White

BioMarin has provided an update on the ABRAZO Phase 2 study of its poly ADP-ribose polymerase (PARP) inhibitor, talazoparib…


BioMarin submits MAA for drisapersen for the treatment of Duchenne muscular dystrophy amenable to exon 51 skipping

Industry news / 8 June 2015 / Victoria White

BioMarin has submitted a MAA for drisapersen for the treatment of the largest subset of Duchenne muscular dystrophy (DMD) amenable to single exon skipping…


First treatment for rare genetic condition

Industry news / 29 April 2014 / BioMarin

The first and only drug designed to address Morquio A syndrome is now available in Europe and the UK for children and adults with this rare genetic condition…


BioMarin provides highlights ahead of research and development day

Industry news, News / 17 September 2013 /

Members of BioMarin’s management team and industry experts will provide an update on the company’s product portfolio and advancements in the research and development pipeline…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...